Palavras-chave
Células-tronco
Ofatumumab
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Comparar a efetividade e aplicabilidade dos tratamentos com anticorpos monoclonais e terapia com células tronco em pacientes com Esclerose Múltipla, por meio de uma revisão de literatura sistemática. Métodos: A pesquisa foi conduzida a partir de uma minuciosa análise da literatura veiculada nas bases de dados PubMed e Cochrane com publicação nos últimos cinco anos. Os descritores utilizados incluíam: “Esclerose Múltipla”, “Anticorpos Monoclonais”, “Ofatumumab” e “Células-Tronco”. Resultados: A análise indica que as terapias investigadas demonstram potencial terapêutico significativo. Os anticorpos monoclonais revelam-se promissores na redução da progressão da incapacidade e na diminuição de taxas de surtos. No contexto das terapias com células-tronco, o transplante autólogo de células-tronco hematopoiéticas destaca-se com resultados promissores na modulação imune e neuroproteção. Não obstante, persistem desafios na definição de diretrizes terapêuticas, em virtude da escassez de estudos comparativos diretos entre as abordagens. Considerações finais: As modalidades terapêuticas estudadas são de suma relevância para o tratamento da Esclerose Múltipla. A seleção da terapia adequada necessita de análise individual, considerando características específicas dos pacientes e o perfil da enfermidade. Torna-se imperativo o estabelecimento de diretrizes, principalmente na avaliação de benefícios e aplicabilidade para cada expressão de Esclerose Múltipla.
Referências
BAR-OR A, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Multiple Sclerosis Journal, 2022; 28(6): 910-924.
BAYAS A, et al. Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical trials. Therapeutic Advances in Neurological Disorders, 2023; 16: 17562864221146836.
BERARD JA, et al. Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. Multiple Sclerosis and Related Disorders, 2022; 61: 103779.
BRITTAIN G, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ open, 2024; 14(2): e083582.
COHEN J, et al. Effect of longer-term ofatumumab treatment on disability progression and brain volume change (S16. 009). Neurology, 2023; 100(17): 2421.
HARRIS VK, et al. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. Neurology: Neuroimmunology & Neuroinflammation, 2020; 8(1): e928.
HARRIS VK, et al. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Research & Therapy, 2024; 15(1): 151.
HAUSER SL, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal, 2022; 28(10): 1576-1590.
HENDRAWAN K, et al. Long-term suppression of circulating proinflammatory cytokines in multiple sclerosis patients following autologous haematopoietic stem cell transplantation. Frontiers in Immunology, 2022; 12: 782935.
JAMALI F, et al. Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study. Cell Transplantation, 2024; 33: 09636897241233045.
KRÅKENES T, et al. The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. PloS one, 2023; 18(11): e0293908.
MARIOTTINI A, et al. Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2023; 78: 104932.
NABAVI SM, et al. Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I/IIa, double blind, randomized controlled study. Multiple Sclerosis and Related Disorders, 2023; 78: 104895.
PARDO G, et al. Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31. 003). In: Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024; 6149.
PETROU P, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain, 2020; 143(12): 3574-3588.
PETROU P, et al. Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Translational Medicine, 2022; 11(1): 55-58.
SOUZA MT, et al. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 2010; 8: 102-106.
TREMBLAY F, et al. Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis. Clinical Neurophysiology, 2022; 136: 69-81.
UCCELLI A, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet Neurology, 2021; 20(11): 917-929.
VISWESWARAN M, et al. Sustained immunotolerance in multiple sclerosis after stem cell transplant. Annals of Clinical and Translational Neurology, 2022; 9(2): 206-220.
WIENDL H, et al. Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010). In: Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024; 5101.